New Terms Of Reference
The AGITG Board recently ratified new organisational documents including Terms of Reference for the Scientific Advisory Committee, Upper... Read More
Consumer network welcomes inquiry
The Senate has announced a national inquiry into the availability of new, innovative and specialist cancer drugs in... Read More
Preceptorship presentation wins prize
The leaders of AGITG’s Preceptorships in Colorectal Cancer, Associate Professor Eva Segelov and Dr Yada Kanjanapan, have won... Read More
Launch of John Zalcberg OAM Award
The AGITG has launched a new clinical trials research award in honour of one of the organisation’s founders. The... Read More
Forums will Engage more regions in 2015
The GI Cancer Institute will reach out into regions across Australia in 2015 with its Engage Community Forums. Three... Read More
New grant will boost AGITG research
The AGITG has announced the launch of a new annual grant of up to $100,000 a year for... Read More
Aspirin-bowel cancer trial seeks recruits
A world-leading international research trial on the use of aspirin in treating bowel cancer is seeking volunteer participants... Read More
NETS therapy funded, new research promises
NSW patients suffering neuroendocrine tumours (NETs) have won a drawn-out battle for funded access to an important treatment... Read More
Building pancreatic cancer awareness
The AGITG has made a hefty contribution to public awareness during November 2014 — International Pancreatic Cancer Awareness... Read More
Rectal cancer surgery trial full
A world-leading AGITG clinical trial on the use of less invasive surgery in the treatment of rectal cancer... Read More
Treating cancer as a whole
Leading Western Australian GI cancer researcher Professor Nik Zeps has told an international TV audience more support is... Read More
Pancreatic cancer drug on PBS
Pancreatic cancer drug Abraxane ® (nanoparticle albumin-bound paclitaxel) is now available under subsidy on the Pharmaceutical Benefits Scheme (PBS), after being listed on November 1. The listing was first recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2014. The Federal Government says more than 1,500 Australian concessional patients stand... Read More
Stomach cancer trial shifts into TOP GEAR
The TOP GEAR trial reached its part 1/phase II recruitment milestone of 120 patients earlier this year (recruitment... Read More
Grant a bonus for less invasive surgery
A world-leading AGITG research trial on the use of less invasive surgery in the treatment of rectal cancer... Read More
Oesophageal cancer: DNA breakthrough
An abnormality in DNA shared by some oesophageal cancer patients discovered by Queensland researchers could be an important... Read More
Engage Forums: November 2014
Three Engage Community Forums on Gastro-Intestinal Cancer will be presented by the GI Cancer Institute / AGITG in... Read More
Korean researchers gain new insights
Dr Boram Han (second from right), pictured in Sydney with AGITG Research Fellows (L-R) Dr Katrin Sjoquist, Dr... Read More
TV appeal for support
GI Cancer Institute and AGITG Executive Officer Russell Conley has told TV audiences in Australia and New Zealand... Read More
Chinese research links sought
Immediate Past Chair of the AGITG, and Current Chair of the AGITG’s new International Development Committee, Professor John... Read More
Aspirin studies “promising”: AGITG
An AGITG Board member has welcomed new findings on the role of aspirin in reducing deaths from bowel... Read More